WTC
DYN icon

WhitTier Trust Company’s Dyne Therapeutics DYN Stock Holding History

WhitTier Trust Company’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.27K Buy
263
+113
+75% +$2.1K ﹤0.01% 1137
2026
Q1 		$2.75K Buy
+150
New +$2.59K ﹤0.01% 1230

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

WhitTier Trust Company's DYN Position: Q2 2026 in Review

WhitTier Trust Company increased its Dyne Therapeutics (DYN) stake by 75% in Q2 2026, buying an estimated $2.1K and bringing the position to 263 shares worth $6.27K. The position accounts for ﹤0.01% of the portfolio, ranked #1137.

WhitTier Trust Company first reported a position in DYN in Q1 2026 and has held it in 2 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • WhitTier Trust Company held 263 shares of Dyne Therapeutics worth $6.27K as of Q2 2026.
  • WhitTier Trust Company bought 113 Dyne Therapeutics shares in Q2 2026, an estimated $2.1K.
  • Dyne Therapeutics made up ﹤0.01% of WhitTier Trust Company's portfolio in Q2 2026, its #1137 holding.
  • WhitTier Trust Company first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on WhitTier Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.